ライフサイエンスコーパス: retinitis

1 stis carinii pneumonia and 1 cytomegalovirus retinitis.

2 ar degeneration, glaucoma, cataract, and CMV retinitis.

3 val of 27.0 years after the diagnosis of CMV retinitis.

4 remote graders evaluated each image for CMV retinitis.

5 ter the initial diagnosis of Cytomegalovirus retinitis.

6 megalovirus disease, notably Cytomegalovirus retinitis.

7 (17%), and the most common manifestation was retinitis.

8 ients may suggest a rise in incidence of CMV retinitis.

9 ompartmental analysis of 1 patient with HCMV retinitis.

10 Among patients without CMV retinitis, 1 of 75 patients with immune recovery develop

11 Of the 21 eyes (10.2%) with CMV retinitis, 7 (33%) had visual symptoms.

12 ating cART and suggest that "immune recovery retinitis," a proposed immune recovery inflammatory synd

13 sed each image as CMV retinitis present, CMV retinitis absent, or unknown.

14 Among persons with CMV retinitis and AIDS, if there is immune recovery, long-te

15 indirect ophthalmoscopy for diagnosis of CMV retinitis and clinical features of CMV retinitis lesions

16 ceived FDA approval to treat cytomegalovirus retinitis and high blood cholesterol, respectively.

17 Bilateral CMV retinitis and larger lesion sizes, each of which is a ma

18 to >/=100 cells/muL; rates of new-onset CMV retinitis and of worsening of CMV retinitis (either incr

19 Sixty-four patients with CMV retinitis and retinal detachment were identified from th

20 the rates of new-onset cytomegalovirus (CMV) retinitis and worsening existing CMV retinitis in patien

21 ), glaucoma, cataract, cytomegalovirus (CMV) retinitis, and low vision.

22 patients who develop active cytomegalovirus retinitis as an immune reconstitution inflammatory syndr

23 ates of retinitis progression and increasing retinitis border activity among patients during the firs

24 dy was not highly sensitive in detecting CMV retinitis but may identify disease with an immediate thr

25 Three control patients with CMV retinitis but no retinal detachment were selected for ea

26 yndrome (AIDS) patients with Cytomegalovirus retinitis (CMVR) -related retinal detachments(RD) in an

27 reduce the likelihood that patients with CMV retinitis develop a retinal detachment.

28 t a cluster of 5 pediatric patients with CMV retinitis diagnosed in a 12-month period and compare thi

29 There were 5 cases of CMV retinitis diagnosed in those transplanted in 2014, a sta

30 -onset CMV retinitis and of worsening of CMV retinitis (either increasing border activity or retiniti

31 sociated multidrug-resistant Cytomegalovirus retinitis in a kidney transplant recipient.

32 ompare the proportion of CMV viremia and CMV retinitis in patients transplanted between January 2010

33 s (CMV) retinitis and worsening existing CMV retinitis in patients with AIDS after initiating combina

34 Our recent cluster of CMV retinitis in pediatric allogeneic HSCT patients may sugg

35 an ophthalmic screening protocol to diagnose retinitis in pediatric HSCT patients in the early, often

36 compare this to the rate of CMV viremia and retinitis in the 4 years prior.

37 patients with immune recovery developed CMV retinitis in the first 6 months after initiating cART vs

38 CMV retinitis nor worsening of existing CMV retinitis in the first 6 months after initiating cART vs

39 The incidence of cytomegalovirus (CMV) retinitis in the pediatric allogeneic hematopoietic stem

40 Telemedicine screening for CMV retinitis instituted at the point of care for human immu

41 Eyes with retinitis involving >/=25% of the retina at presentation

42 Cytomegalovirus (CMV) retinitis is a leading cause of blindness in many develo

43 Cytomegalovirus retinitis is a serious infection because of the risk of

44 Cytomegalovirus retinitis is an uncommon opportunistic infection in kidn

45 The CMV retinitis lesions missed by the remote graders (false-ne

46 Retinitis lesions occupied less than 10% of the total re

47 f CMV retinitis and clinical features of CMV retinitis lesions.

48 The occurrence of Cytomegalovirus retinitis may help improve the selection of patients con

49 Initial misdiagnosis as retinitis (n = 5), hemangioma (n = 1), choroidal neovasc

50 s neither an increased rate of new-onset CMV retinitis nor worsening of existing CMV retinitis in the

51 atients (15.5%) were diagnosed as having CMV retinitis, of whom 5 (31%) had bilateral disease.

52 ty for the 3 remote graders in detecting CMV retinitis on fundus photography was 30.2% (95% CI, 10.5%

53 Three of 17 patients (18%) showed retinitis or uveitis without optic neuropathy.

54 athy, with 12 of these patients also showing retinitis or uveitis.

55 ith paraneoplastic optic neuritis, vitritis, retinitis, or a combination thereof, but few reports of

56 c disc edema, often associated with uveitis, retinitis, or both.

57 MW-opsin enables an otherwise blind retinitis pigmenotosa mouse to discriminate temporal and

58 Taking advantage of a mouse model of retinitis pigmentosa ( Rho(P23H/P23H)), we clarified the

59 ular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16)

60 The cause of autosomal-dominant retinitis pigmentosa (adRP), which leads to loss of visi

61 ation is a major cause of autosomal dominant retinitis pigmentosa (adRP).

62 (n = 80) or autosomal recessive nonsyndromic retinitis pigmentosa (ARRP) (n = 47) associated with bia

63 EYS are associated with autosomal recessive retinitis pigmentosa (arRP) and autosomal recessive cone

64 otype in 4 families with autosomal recessive retinitis pigmentosa (arRP) that can be associated with

65 and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in mammalian oocytes using

66 DNA, associated with neuropathy, ataxia, and retinitis pigmentosa (NARP).

67 We analyze disease progression in retinitis pigmentosa (RP) according to mode of inheritan

68 Retinitis pigmentosa (RP) affects about 1.8 million indi

69 Outer retinal degenerative diseases, such as retinitis pigmentosa (RP) and age-related macular degene

70 ness in a number of retinal diseases such as retinitis pigmentosa (RP) and atrophic age-related macul

71 ncurable blinding retinal diseases including retinitis pigmentosa (RP) and atrophic age-related macul

72 d and irreversible disease that manifests as retinitis pigmentosa (RP) and bilateral neurosensory hea

73 e Leber congenital amaurosis (LCA), juvenile retinitis pigmentosa (RP) and cone-rod dystrophy.

74 generation and clinical phenotypes including retinitis pigmentosa (RP) and congenital stationary nigh

75 For ill-defined reasons, CS degenerate in retinitis pigmentosa (RP) and in the transitional zone (

76 ripherin 2 (PRPH2) have been associated with retinitis pigmentosa (RP) and macular/pattern dystrophie

77 d to various retinal degenerations including retinitis pigmentosa (RP) and macular/pattern dystrophy

78 Retinitis pigmentosa (RP) are a group of incurable and i

79 etal developmental defects and non-syndromic retinitis pigmentosa (RP) are frequent findings.

80 Stargardt's disease (STGD) and Retinitis Pigmentosa (RP) are inherited retinal degenera

81 eber congenital amaurosis (LCA) and juvenile retinitis pigmentosa (RP) are severe hereditary diseases

82 oherence tomography (SDOCT) in patients with retinitis pigmentosa (RP) associated with retinitis pigm

83 Retinitis pigmentosa (RP) encompasses a diverse group of

84 Cystoid macular edema (CME) in retinitis pigmentosa (RP) has been managed in several wa

85 Several mutations in PRCD are linked to retinitis pigmentosa (RP) in canines and humans, and whi

86 Retinitis pigmentosa (RP) is a blinding disease caused b

87 Retinitis pigmentosa (RP) is a blinding disease often as

88 Retinitis pigmentosa (RP) is a debilitating blinding dis

89 Retinitis pigmentosa (RP) is a disease that initially pr

90 Retinitis pigmentosa (RP) is a genetically heterogenous

91 Retinitis pigmentosa (RP) is a group of blinding disorde

92 Retinitis pigmentosa (RP) is a group of inherited retina

93 Retinitis pigmentosa (RP) is a group of inherited retina

94 Retinitis pigmentosa (RP) is a heterogeneous group of in

95 Retinitis pigmentosa (RP) is a highly heterogeneous grou

96 Retinitis pigmentosa (RP) is a major cause of blindness

97 Photoreceptor degeneration due to retinitis pigmentosa (RP) is a primary cause of inherite

98 Retinitis pigmentosa (RP) is an incurable neurodegenerat

99 Retinitis pigmentosa (RP) is an inherited neurodegenerat

100 Retinitis pigmentosa (RP) is an inherited photoreceptor

101 Retinitis pigmentosa (RP) is an inherited photoreceptor-

102 Retinitis pigmentosa (RP) is an inherited retinal degene

103 Retinitis pigmentosa (RP) is an inherited retinal degene

104 ted for some RP cases.SIGNIFICANCE STATEMENT Retinitis pigmentosa (RP) is an inherited, degenerative

105 associated with the various genetic forms of retinitis pigmentosa (RP) is currently untreatable and l

106 Retinitis pigmentosa (RP) is described as a bilateral di

107 Retinitis pigmentosa (RP) is the most common form of inh

108 Retinitis pigmentosa (RP) is the most frequent form of i

109 Because the secondary loss of cones in retinitis pigmentosa (RP) leads to blindness, the admini

110 some vision to patients blind as a result of retinitis pigmentosa (RP) or outer retinal degeneration.

111 t, we assess the natural progression rate of retinitis pigmentosa (RP) over an average of three years

112 analyze the genetic and clinical findings in retinitis pigmentosa (RP) patients of Ashkenazi Jewish (

113 cing (NGS) based molecular diagnosis for 105 Retinitis Pigmentosa (RP) patients randomly selected fro

114 in mislocalization is frequently observed in retinitis pigmentosa (RP) patients.

115 vel the molecular pathogenesis of an unusual retinitis pigmentosa (RP) phenotype observed in a Turkis

116 A retinitis pigmentosa (RP) phenotype was present in 50 pa

117 e limited published data on the phenotype of retinitis pigmentosa (RP) related to CNGB1 variants.

118 Patients diagnosed with Retinitis Pigmentosa (RP) show, in the advanced stage of

119 Retinitis pigmentosa (RP) shows progressive loss of phot

120 USH2A mutations are an important cause of retinitis pigmentosa (RP) with or without congenital sen

121 Retinitis pigmentosa (RP), a heterogeneous group of inhe

122 therapy has shown great promise in treating retinitis pigmentosa (RP), a primary photoreceptor degen

123 cells, are the most common cause of dominant retinitis pigmentosa (RP), a type of inherited blindness

124 tinal and brain pathologies, but its role in retinitis pigmentosa (RP), an inherited and largely incu

125 by congenital sensorineural hearing loss and retinitis pigmentosa (RP), and also contribute to autoso

126 retinal diseases, such as Stargardt disease, retinitis pigmentosa (RP), and atrophic age-related macu

127 viously reported to cause autosomal dominant retinitis pigmentosa (RP), and described their detailed

128 mans, such as Leber congenital amaurosis and retinitis pigmentosa (RP), are attributed to either homo

129 itary retinal degenerative diseases, such as retinitis pigmentosa (RP), are characterized by the prog

130 unrelated families with autosomal recessive retinitis pigmentosa (RP), but without extraocular invol

131 indings in patients with autosomal recessive retinitis pigmentosa (RP), cone-rod dystrophy (CRD) or c

132 individuals, it was found to segregate with retinitis pigmentosa (RP), goiter, primary ovarian insuf

133 y photoreceptor cells and cause nonsyndromic retinitis pigmentosa (RP), raising the issue of why cert

134 BACKGROUNDIn retinitis pigmentosa (RP), rod photoreceptors degenerate

135 involved in O-mannosyl glycosylation, cause retinitis pigmentosa (RP), RP25 and RP76, respectively.

136 Retinitis pigmentosa (RP), the most common form of rod-c

137 composed of IRD two with autosomal dominant retinitis pigmentosa (RP), two with autosomal recessive

138 rlying cause of many ciliopathies, including Retinitis Pigmentosa (RP).

139 t surgery accelerates disease progression in retinitis pigmentosa (RP).

140 r partial restoration of vision in end-stage retinitis pigmentosa (RP).

141 dominant P23H rhodopsin mutation that causes retinitis pigmentosa (RP).

142 to treat retinal degenerative diseases like retinitis pigmentosa (RP).

143 alth, and employment among young adults with retinitis pigmentosa (RP).

144 ith unknown function that is associated with retinitis pigmentosa (RP).

145 orm of degenerative human blindness known as retinitis pigmentosa (RP).

146 S), Bardet-Biedl Syndrome, and some forms of retinitis pigmentosa (RP).

147 he change in the outer retinal structures in retinitis pigmentosa (RP).

148 ding is a common cause of autosomal dominant retinitis pigmentosa (RP).

149 enotype of the Rh1(G69D) Drosophila model of retinitis pigmentosa (RP).

150 o restore some vision in patients blinded by retinitis pigmentosa (RP).

151 or, are a common cause of autosomal dominant retinitis pigmentosa (RP).

152 P1 lead to recessive or dominantly inherited retinitis pigmentosa (RP).

153 ked to various ocular impairments, including retinitis pigmentosa (RP).

154 in the Tulp1 gene cause severe, early-onset retinitis pigmentosa (RP14) in humans.

155 phenotype groups were identified in EYS-RD: retinitis pigmentosa (RP; 85.94%), cone-rod dystrophy (C

156 d to unravel the molecular basis of sporadic retinitis pigmentosa (sRP) in the largest cohort reporte

157 tor (RPGR) gene account for >70% of X-linked retinitis pigmentosa (XLRP) and 15-20% of all inherited

158 tations in the human RP2 gene cause X-linked retinitis pigmentosa (XLRP) and cone-rod dystrophy (XL-C

159 ation (M58K) found in a family with X-linked retinitis pigmentosa (XLRP) and show that this missense

160 X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blindi

161 ges of disease in a canine model of X-linked retinitis pigmentosa (XLRP) caused by a mutation in the

162 X-linked retinitis pigmentosa (XLRP) is one of the most severe fo

163 in the pathogenesis associated with X-linked retinitis pigmentosa (XLRP) resulting from mutations in

164 RPGR genes are responsible for the X-linked retinitis pigmentosa (XLRP).

165 an RPGR point mutation that causes X-linked retinitis pigmentosa (XLRP).

166 ases are caused by mutations in the X-linked retinitis pigmentosa 2 (RP2) and RPGR.

167 s regulatory GTPase activating protein (GAP) Retinitis Pigmentosa 2 (RP2).

168 tions in the ARL3 GTPase activating protein, retinitis pigmentosa 2 (RP2).

169 The retinitis pigmentosa 2 polypeptide (RP2) functions as a

170 ilies diagnosed as having autosomal dominant retinitis pigmentosa and 10% in families with variable c

171 itry, degenerate in retinal diseases such as retinitis pigmentosa and age related macular degeneratio

172 ntion of blinding degenerative diseases like retinitis pigmentosa and age-related macular degeneratio

173 use of untreatable blindness worldwide, with retinitis pigmentosa and cone dystrophy affecting approx

174 al degeneration and visual disorders such as retinitis pigmentosa and congenital stationary night bli

175 ndrome known as Short stature, Hearing loss, Retinitis pigmentosa and distinctive Facies (SHRF, #OMIM

176 s that BBS2 mutations can cause nonsyndromic retinitis pigmentosa and highlights yet another candidat

177 Degenerative retinal diseases such as retinitis pigmentosa and macular degeneration cause irre

178 lly used during neurodegeneration arising in retinitis pigmentosa and prion infection.

179 Rod-cone degenerations, for example, retinitis pigmentosa are leading causes of blindness wor

180 We further found that PRPF8 mutants causing Retinitis pigmentosa assemble less efficiently with the

181 lium (RPE) from an individual suffering from retinitis pigmentosa associated with biallelic variants

182 X-linked retinitis pigmentosa can manifest in female carriers wit

183 ncharacterized cohort of autosomal recessive retinitis pigmentosa cases.

184 this issue in an established mouse model of Retinitis Pigmentosa caused by the P23H mutation in rhod

185 tified homozygous REEP6-E75K mutation in two retinitis pigmentosa families of different ethnicities.

186 etinal degeneration in XLRP.Mutations in the Retinitis Pigmentosa GTPase Regulator (RPGR) cause retin

187 Mutations in the Retinitis Pigmentosa GTPase Regulator (RPGR) cause X-lin

188 Mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene accoun

189 Mutations in the X-linked retinitis pigmentosa GTPase regulator (RPGR) gene are a

190 Mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene cause

191 igmentosa (XLRP) caused by a mutation in the Retinitis Pigmentosa GTPase Regulator (RPGR) gene.

192 th retinitis pigmentosa (RP) associated with retinitis pigmentosa GTPase regulator gene (RPGR) mutati

193 ogression rates, and interocular symmetry in retinitis pigmentosa GTPase regulator gene (RPGR)-associ

194 addition, SPATA7 directly interacts with the retinitis pigmentosa GTPase regulator interacting protei

195 Mutations in the ciliary protein RPGR (retinitis pigmentosa GTPase regulator) are a prominent c

196 Mutations in the ciliary protein RPGR (retinitis pigmentosa GTPase regulator) are common causes

197 Mutations in RPGR (retinitis pigmentosa GTPase regulator) are the most comm

198 y leading to decreased expression of FTO and retinitis pigmentosa GTPase regulator-interacting protei

199 It is unclear how genes, such as RPGR (retinitis pigmentosa guanine triphosphatase regulator) t

200 horoidal neovascularization in 2.3% of eyes; retinitis pigmentosa in 1.9% of eyes; severe cough in 1.

201 etinal dystrophy in 82% (19/23), followed by retinitis pigmentosa in 14% (3/23) and cone-rod dystroph

202 e defect was reported in human patients with retinitis pigmentosa in 1993.

203 mice and, therefore, may not be causative of retinitis pigmentosa in humans.

204 The mutations cosegregated with retinitis pigmentosa in the studied families, and the af

205 Retinitis pigmentosa is a devastating, blinding disorder

206 Retinitis Pigmentosa is a group of hereditary retinal dy

207 Retinitis pigmentosa is a leading cause of inherited bli

208 Retinitis pigmentosa is a progressive retinal dystrophy

209 Retinitis pigmentosa is a rare disease, affecting only a

210 Retinitis pigmentosa is a retinal degenerative disease t

211 PRPF31-mediated retinitis pigmentosa is characterized by a variable age

212 d CRB1 and CRB2 gene therapy vectors in Crb1-retinitis pigmentosa mouse models at mid-stage disease.

213 Several human diseases, such as retinitis pigmentosa or congenital night blindness, are

214 deficiency is linked to human diseases like retinitis pigmentosa or myeloid neoplasia, but its genom

215 specific visual cortical gray matter loss in Retinitis Pigmentosa patients associated with their visu

216 is likely the cause of phenotype observed in retinitis pigmentosa patients carrying T17M mutation.

217 We also find that MG from retinitis pigmentosa patients display an increase in Bre

218 Retinitis pigmentosa patients from 230 families of AJ or

219 tter volume has not been addressed before in Retinitis Pigmentosa patients with low vision.

220 whole brain gray matter volume changes in 27 Retinitis Pigmentosa patients with partially preserved v

221 of several rhodopsin mutations identified in retinitis pigmentosa patients, including F220C and F45L,

222 PRPF31-associated retinitis pigmentosa presents a fascinating enigma: some

223 Vision impairments and blindness caused by retinitis pigmentosa result from severe neurodegeneratio

224 Retinitis pigmentosa results in blindness due to degener

225 ere autosomal recessive retinal dystrophies (retinitis pigmentosa RP64 and cone-rod dystrophy CORD16)

226 higher photosynthetic organisms, as well as Retinitis Pigmentosa Type 2-Clathrin Light Chain, a memb

227 tegies to optimize outcomes in patients with retinitis pigmentosa undergoing retinal prosthesis impla

228 disease, age-related macular degeneration or retinitis pigmentosa urgently require the development of

229 Retinitis pigmentosa was observed in 5/10 (50%) of the M

230 udinal imaging follow-up in 71 patients with retinitis pigmentosa was studied using the main outcome

231 ient demonstrated an unexpected diagnosis of retinitis pigmentosa with a novel variant of unknown sig

232 o groups of patients suffering from advanced retinitis pigmentosa with specific deterioration of the

233 understanding other dominant diseases (e.g., retinitis pigmentosa) caused by missense mutations in me

234 ilies with a diagnosis of autosomal dominant retinitis pigmentosa, 35 families with unspecified macul

235 e regulator (RPGR) gene are a major cause of retinitis pigmentosa, a blinding retinal disease resulti

236 In a genetic mutant model of retinitis pigmentosa, a lead compound, Q525, afforded su

237 Patients affected by retinitis pigmentosa, an inherited retinal disease, expe

238 ular age-related macular degeneration (AMD), retinitis pigmentosa, and diabetic retinopathy are assoc

239 nvolved in age-related macular degeneration, retinitis pigmentosa, and Leber's congenital amaurosis m

240 the proband presents with hepatic fibrosis, retinitis pigmentosa, and postaxial polydactyly; he harb

241 sing CRISPR/Cas9 to model the human disorder retinitis pigmentosa, and to introduce point mutations o

242 tics with potential applications not only in retinitis pigmentosa, but also in age-related macular de

243 Twelve DEGs were associated with retinitis pigmentosa, characterized by dystrophy of the

244 macular degeneration (wet AMD), Luxturna for retinitis pigmentosa, Dextenza (0.4 mg dexamethasone int

245 In retinitis pigmentosa, loss of cone photoreceptors leads

246 tained families with a clinical diagnosis of retinitis pigmentosa, macular dystrophy, and/or pattern

247 In a mouse model of retinitis pigmentosa, monotherapy with a small-molecule

248 d deletion of codon 153 (K153Delta) leads to retinitis pigmentosa, pattern dystrophy, and fundus flav

249 d attenuate photoreceptor loss in a model of retinitis pigmentosa, the P23H transgenic rat.

250 Retinitis pigmentosa, which affects one in 3000 people,

251 he RPGR gene cause a common form of X-linked retinitis pigmentosa, which often results in severe loss

252 ophy and some exhibited macular dystrophy or retinitis pigmentosa, while all presented with macular d

253 encing or high-throughput sequencing for all retinitis pigmentosa-associated genes in patients, and s

254 t use, to our knowledge, of human iPSCs with retinitis pigmentosa-causing mutations to look at pathop

255 th cone-rod dystrophy (CORD), and three with retinitis pigmentosa.

256 promising treatment option for patients with retinitis pigmentosa.

257 ses and visual behaviors in rodent models of Retinitis pigmentosa.

258 ntal retardation, and one subject exhibiting retinitis pigmentosa.

259 resembling a dry desert land and ends with a retinitis pigmentosa.

260 nts from the Trial of Oral Valproic Acid for Retinitis Pigmentosa.

261 henotype in rd10 mice, a model for inherited retinitis pigmentosa.

262 ents with retinal degenerative diseases like retinitis pigmentosa.

263 in a rhodopsin knockout (RKO) mouse model of retinitis pigmentosa.

264 s in retinal wholemounts in a mouse model of retinitis pigmentosa.

265 model of the retinal degeneration condition retinitis pigmentosa.

266 spicule-like pigmented deposits, typical for retinitis pigmentosa.

267 (BBS), Leber congenital amaurosis (LCA), and retinitis pigmentosa.

268 macular degeneration, Stargardt disease, and retinitis pigmentosa.

269 2 missense mutations that cause nonsyndromic retinitis pigmentosa.

270 acular degeneration, retinal detachment, and retinitis pigmentosa.

271 e RP2 gene lead to a severe form of X-linked retinitis pigmentosa.

272 of a small protein therapy for some forms of retinitis pigmentosa.

273 t-Biedl syndrome usually develop early-onset retinitis pigmentosa.

274 electroretinogram confirmed the diagnosis of retinitis pigmentosa.

275 the most common cause of autosomal dominant retinitis pigmentosa.

276 when subretinally injected in a rat model of retinitis pigmentosa.

277 transgenic mouse as a preclinical model for retinitis pigmentosa.

278 eneration pedigree affected predominantly by retinitis pigmentosa.

279 ve Leber congenital amaurosis to later onset retinitis pigmentosa.

280 cavefish resemble retinal diseases, such as retinitis pigmentosa.

281 outer retinal degeneration diseases such as retinitis pigmentosa.

282 models of both multiple sclerosis and human retinitis pigmentosa.

283 Leigh syndrome and 7 with neuropathy ataxia retinitis pigmentosa.

284 is the mouse counterpart of 1 type of human retinitis pigmentosa.

285 used in gene therapy studies seeking to cure retinitis pigmentosa.

286 st 1 eye), and a negative family history for retinitis pigmentosa.

287 Graders diagnosed each image as CMV retinitis present, CMV retinitis absent, or unknown.

288 ng patients with CMV retinitis, the rates of retinitis progression and increasing retinitis border ac

289 initis (either increasing border activity or retinitis progression) were compared between those with

290 an be effective in improving VA and limiting retinitis progression.

291 clinic for HIV treatment had less extensive retinitis than patients in recent reports from an ophtha

292 at the time of the initial diagnosis of CMV retinitis that predicted subsequent retinal detachment i

293 Among patients with CMV retinitis, the rates of retinitis progression and increa

294 The combination of retinitis, vitritis, and optic disc edema without optic

295 so for the initial clinic visit at which CMV retinitis was diagnosed.

296 characteristics of patients with active CMV retinitis were described.

297 No cases of CMV retinitis were identified.

298 al of 13.5 months after the diagnosis of CMV retinitis, whereas those with immune recovery had a mort

299 CMV retinitis without HIV infection was often aggressive at

300 Consecutive patients with CMV retinitis without HIV infection were reviewed.